《大行報告》摩通上調中生製藥(01177.HK)目標價至13.5元 評級「增持」
摩根大通發表研究報告指,計及中生製藥(01177.HK)於科興疫苗的投資,以及多款新藥產品進入後期階段,實現盈利可期,對其看法正面,將目標價由9元提升至13.5元。
摩通表示,中生製藥的股價自去年12月的谷底已反彈約26%,對比同期MSCI中國健康護理指數升約17%,相信主要是由於投資者憧憬公司對科興疫苗的15%投資可提供可觀盈利。摩通預測2021至2023年科興疫苗將對淨利貢獻至少36%至51%,予「增持」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.